TWI700493B - 用於非侵入性肝癌診斷之特異性生物標記組 - Google Patents

用於非侵入性肝癌診斷之特異性生物標記組 Download PDF

Info

Publication number
TWI700493B
TWI700493B TW103126171A TW103126171A TWI700493B TW I700493 B TWI700493 B TW I700493B TW 103126171 A TW103126171 A TW 103126171A TW 103126171 A TW103126171 A TW 103126171A TW I700493 B TWI700493 B TW I700493B
Authority
TW
Taiwan
Prior art keywords
biomarker
autoantibodies
primary
hcc
conjugated
Prior art date
Application number
TW103126171A
Other languages
English (en)
Chinese (zh)
Other versions
TW201602579A (zh
Inventor
詠賢 文
鳳文 衞
炳鏐 黃
智賢 衛
Original Assignee
香港商龍勝發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by 香港商龍勝發展有限公司 filed Critical 香港商龍勝發展有限公司
Publication of TW201602579A publication Critical patent/TW201602579A/zh
Application granted granted Critical
Publication of TWI700493B publication Critical patent/TWI700493B/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
TW103126171A 2014-07-02 2014-07-31 用於非侵入性肝癌診斷之特異性生物標記組 TWI700493B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 2014-07-02
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 2014-07-02

Publications (2)

Publication Number Publication Date
TW201602579A TW201602579A (zh) 2016-01-16
TWI700493B true TWI700493B (zh) 2020-08-01

Family

ID=55019816

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103126171A TWI700493B (zh) 2014-07-02 2014-07-31 用於非侵入性肝癌診斷之特異性生物標記組

Country Status (12)

Country Link
EP (1) EP3164711A4 (cg-RX-API-DMAC10.html)
JP (2) JP2017520763A (cg-RX-API-DMAC10.html)
KR (1) KR102086788B1 (cg-RX-API-DMAC10.html)
CN (2) CN105319362B (cg-RX-API-DMAC10.html)
AU (2) AU2014399919B2 (cg-RX-API-DMAC10.html)
CA (1) CA2939912C (cg-RX-API-DMAC10.html)
MY (2) MY195045A (cg-RX-API-DMAC10.html)
NZ (1) NZ722492A (cg-RX-API-DMAC10.html)
SG (1) SG11201606106SA (cg-RX-API-DMAC10.html)
TW (1) TWI700493B (cg-RX-API-DMAC10.html)
UY (1) UY36200A (cg-RX-API-DMAC10.html)
WO (1) WO2016003479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (zh) * 2016-09-02 2020-03-17 四川大学 一种诊断肝癌的标记物组合及其应用
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (ko) 2019-03-13 2020-11-06 충남대학교산학협력단 Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물
CN110646615B (zh) * 2019-08-27 2021-07-13 南方医科大学 肝纤维化的生物学标志物、治疗靶点及其用途
WO2021072275A1 (en) 2019-10-11 2021-04-15 Guardant Health, Inc. Use of cell free bacterial nucleic acids for detection of cancer
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (zh) * 2021-05-27 2021-10-15 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108553A1 (en) * 2001-09-19 2003-06-12 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
WO2003058201A2 (en) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (ja) * 2003-08-31 2007-08-15 株式会社イムノディア 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
CA2567987A1 (en) * 2004-06-18 2005-12-29 Gabriele Pestlin Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (ja) * 2010-08-25 2014-05-14 国立大学法人山口大学 自己抗体の検出方法
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
US20130130355A1 (en) * 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108553A1 (en) * 2001-09-19 2003-06-12 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker

Also Published As

Publication number Publication date
JP2017520763A (ja) 2017-07-27
CN107478842B (zh) 2020-10-16
AU2017232129B2 (en) 2018-10-25
CN105319362B (zh) 2018-07-13
CN107478842A (zh) 2017-12-15
AU2014399919B2 (en) 2019-10-24
HK1224370A1 (zh) 2017-08-18
UY36200A (es) 2016-01-29
MY179845A (en) 2020-11-18
KR20170021234A (ko) 2017-02-27
CA2939912C (en) 2019-04-16
KR102086788B1 (ko) 2020-03-09
HK1248803A1 (zh) 2018-10-19
MY195045A (en) 2023-01-04
NZ722492A (en) 2019-09-27
TW201602579A (zh) 2016-01-16
CA2939912A1 (en) 2016-01-07
EP3164711A4 (en) 2018-05-23
AU2014399919A1 (en) 2016-08-11
JP2020160082A (ja) 2020-10-01
WO2016003479A1 (en) 2016-01-07
AU2017232129A1 (en) 2017-10-12
SG11201606106SA (en) 2016-08-30
CN105319362A (zh) 2016-02-10
EP3164711A1 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
CN105319362B (zh) 用于肝癌的无创诊断的特异性生物标志物组
Wagner et al. Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence
KR20190005858A (ko) 어레이 방법 및 그의 용도
Wu et al. Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma
CA3213677A1 (en) Citrullinated proteins as biomarkers and therapy targets for cancer
KR102617206B1 (ko) 췌장암 및 췌장관 내 유두상 점액성 종양의 마커
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
JP6639408B2 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
US20200386761A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
US7718393B2 (en) Method for determining the efficacy of an anthracycline anticancer agent
US10620209B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
US9885718B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
JP2008527984A (ja) 癌及び結腸直腸癌性障害の診断及び療法のためのｔｉｆ１−ベータペプチド及び核酸
Wang et al. Clinical and prognostic significance of CCPG1 in hepatocellular carcinoma.
HK1224370B (en) Specific biomarker set for non-invasive diagnosis of liver cancer
HK1248803B (en) Specific biomarker set for non-invasive diagnosis of liver cancer
Karakaş et al. Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy
JP2009192527A (ja) 癌マーカー及び癌細胞の検査方法
Polanco Comparative Proteomic Analysis Of Extracellular Vesicles From Prostate Cancer-Derived Cell Lines
JP2012225822A (ja) ＡＰＣ−ｂｉｎｄｉｎｇｐｒｏｔｅｉｎＥＢ１を用いた大腸癌の診断、治療法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees